Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC–MAX Heterodimerization
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c02556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Oluwatosin A Obisesan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, Division of Chemistry.
Abstract (Originalsprache)
c-MYC is an oncogenic transcription factor that plays a crucial role in the regulation of downstream targets involved in proliferation, apoptosis, differentiation, metabolism, signaling, and immune response processes whose deregulation leads to the progression of different pathologies. The development of selective and potent small-molecule inhibitors of c-MYC remains a grand challenge in chemical biology and medicine due to its undruggability, derived from extensive intrinsic disorder. In this study, we identified a novel dihydro pyrazolo pyridinone scaffold, MY05, that selectively targets c-MYC in cells and disrupts MYC-MAX interaction. MY05 engages intracellular c-MYC, modulates c-MYC thermal stability, reduces c-MYC transcriptional targets, and inhibits proliferation in cancer cells and tumor growth in mice. In summary, we identified a novel compound that directly interacts with c-MYC to disrupt the transcriptional program.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, University of Kentucky, Lexington, Kentucky 40506, United States.
- Center for Pharmaceutical Research and Innovation, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky 40536, United States.
- Markey NCI Comprehensive Cancer Center, University of Kentucky, Lexington, Kentucky 40536, United States.
- University of Kentucky Bioelectronics and Nanomedicine Research Center, Lexington, Kentucky 40506, United States.
ORCID-Profile: Oluwatosin A Obisesan, Samuel G Awuah
Förderung
- NIGMS NIH HHS
- NCI NIH HHS
- Division of Chemistry
- National Institute of General Medical Sciences
Zitieren
APA
Obisesan, O. A., Ofori, S., Orobator, O. N., Sharma, H., Groetecke, E., & Awuah, S. G. (2025). Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC–MAX Heterodimerization. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c02556
Vancouver
Obisesan OA, Ofori S, Orobator ON, Sharma H, Groetecke E, Awuah SG. Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC–MAX Heterodimerization. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c02556
BibTeX
@article{Obisesan2025,
author = {Obisesan, Oluwatosin A and Ofori, Samuel and Orobator, Owamagbe N and Sharma, Himanshi and Groetecke, Emma and Awuah, Samuel G},
title = {Discovery of a Pyrazolopyridinone-Based MYC Inhibitor That Selectively Engages Intracellular c-MYC and Disrupts MYC–MAX Heterodimerization},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c02556}
}
EUVIMED